PR Newswire: news distribution, targeting and monitoring
2014

Telik Announces Second Quarter 2012 Financial Results

Share with Twitter Share with LinkedIn

PALO ALTO, Calif., Aug. 10, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $2.1 million, or $1.11 per share, for the second quarter ended June 30, 2012, compared with a net loss of $3.0 million, or $1.67 per share (adjusted for the 1-for-30 reverse split of the company's common stock effected on March 30, 2012), for the comparable period in 2011.

For the quarter ended June 30, 2012, total operating costs and expenses were $2.1 million, compared with $3.0 million in the 2011 second quarter.  Operating expenses in the 2012 second quarter included stock-based compensation expense of approximately $0.2 million. Operating expenses were approximately 32% lower in the second quarter of 2012 compared with the same period in 2011, primarily due to lower headcount, lower stock-based compensation expense and lower corporate administrative costs.

For the six months ended June 30, 2012, Telik reported a net loss of $4.3 million, or $2.36 per share, compared with a net loss of $6.7 million, or $3.72 per share (adjusted for the 1-for-30 reverse stock split), for the six months ended June 30, 2011.  Total operating expenses for the first six months of 2012 were $4.3 million, compared with $6.7 million for the first six months of 2011.  Operating expenses in the first six months of 2012 included approximately $0.4 million in stock-based compensation expense.  The reduction in operating expenses of approximately 35% in the first six months of 2012 compared with the same period in 2011 was primarily due to lower headcount and stock-based compensation expenses, lower clinical development and related costs, and lower corporate expenses.

At June 30, 2012, Telik had $8.1 million in cash, cash equivalents and investments including restricted investments, compared to $11.7 million at December 31, 2011. In order to meet its cash requirements beyond 2012, the company will have to raise additional funds through corporate partnering or equity financings.  Although the company has been able to raise funds through its At Market Issuance Sales Agreement, there is no assurance Telik will be successful in obtaining additional funding in the future.

About Telik

Telik, Inc. of Palo Alto, CA is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.  Additional information is available at www.telik.com.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

Telik, Inc.

Statements of Operations

(In thousands, except per share amounts)

(Unaudited)
























Three Months Ended 


Six Months Ended




June 30,


June 30,




2012


2011


2012


2011











Operating costs and expenses:









Research and development 

$           932


$        1,465


$        1,921


$        3,159


General and administrative 

1,123


1,546


2,412


3,540



Total operating costs and expenses

2,055


3,011


4,333


6,699











Loss from operations

(2,055)


(3,011)


(4,333)


(6,699)











Interest and other income (expense), net

3


10


4


24

Net loss

$       (2,052)


$       (3,001)


$       (4,329)


$       (6,675)











Basic and diluted net loss per share

$         (1.11)


$         (1.67)


$         (2.36)


$         (3.72)











Weighted average shares used to calculate basic 









and diluted net loss per share

1,849


1,799


1,832


1,794



















































Selected Balance Sheet Data





(In thousands)





(Unaudited)


















June 30,


December 31,








2012


2011















Cash, cash equivalents, investments and restricted investments

$        8,054


$      11,700















Total assets

$        8,750


12,412















Stockholders' equity

$        5,553


8,299















SOURCE Telik, Inc.



RELATED LINKS
http://www.telik.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release